X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Endo obtained the rights to abaloparatide-subcutaneous injection and abaloparatide-transdermal patch, a novel formulation and route of administration currently undergoing clinical development. Endo, will be responsible for all commercial activities related to abaloparatide.
Lead Product(s): Abaloparatide Acetate
Therapeutic Area: Musculoskeletal Product Name: BA058
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Endo International
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 05, 2021
Details:
The license agreement is initially focused on the development and commercialization of arfolitixorin as first-line treatment for metastatic colorectal cancer (mCRC) patients in Japan, which is projected to be the second largest addressable patient market for arfolitixorin.
Lead Product(s): Arfolitixorin,Oxaliplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Isofol Medical
Deal Size: $100.0 million Upfront Cash: $103.0 million
Deal Type: Licensing Agreement November 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
